机译:使用正交IL-2细胞因子-受体复合物选择性靶向工程化T细胞
Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA;
Univ Calif San Francisco, Diabet Ctr, San Francisco, CA 94143 USA;
Univ Calif Los Angeles, Div Hematol Oncol, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA;
Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA;
Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA;
Stanford Univ, Sch Med, Dept Blood & Marrow Transplantat, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA;
Stanford Univ, Sch Med, Dept Blood & Marrow Transplantat, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA;
Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA;
Stanford Univ, Sch Med, Dept Pediat & Genet, Stanford, CA 94305 USA;
Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA;
Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA;
Stanford Univ, Sch Med, Dept Blood & Marrow Transplantat, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA;
Parker Inst Canc Immunotherapy, 1 Letterman Dr,Suite D3500, San Francisco, CA 94129 USA;
Univ Calif San Francisco, Diabet Ctr, San Francisco, CA 94143 USA;
Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA;
机译:IL-2 / CD25:通过在调节性T细胞上选择性靶向IL-2受体来促进免疫耐受的长效融合蛋白
机译:690?CD122选择性IL-2复合物治疗卵巢癌,诱导Treg脆性并促进T细胞干细胞
机译:IL-2和T细胞受体信号通路的差异靶向可选择性扩展调节性T细胞,同时抑制常规T细胞
机译:使用嵌合IL-2受体进行癌症治疗的基因改性T细胞的选择性扩张
机译:经过工程改造以过度表达IL-2,IL-7,IL-15或IL-21的肿瘤特异性人类原代T细胞可在免疫缺陷小鼠模型中赋予不同程度的肿瘤排斥反应和异种移植物抗宿主病。
机译:使用正交IL-2细胞因子-受体复合物选择性靶向工程化T细胞
机译:使用正交IL-2 / IL-2受体系统选择性扩增调节性T细胞有助于移植耐受性